Abstract

**Background:** This review article examines updates to the literature during the past 5 years on numerous topics which were felt to have ongoing controversy. These topics include venous thromboprophylaxis, tranexamic acid usage, tourniquet usage, and wound closure techniques.

**Methods:** For each individual topic, a literature search was conducted on several databases with emphasis on studies that were published in the past 5 years. Preference was given to meta-analyses and randomized controlled trials.

**Results:** Tranexamic acid is a safe and effective treatment modality, and consideration should be given to use multiple doses and combine different modes of administration. Certain treatment modalities (skin sutures, limited or no tourniquet usage) can cause greater patient satisfaction at a cost of longer operating times. Postoperative anticoagulation is still a very controversial topic. There is however some evidence suggesting prolonging anticoagulation to 35 days postoperative.

**Conclusions:** By analyzing the results of the aforementioned studies, surgeons can implement the most up-to-date evidence-based care when doing total knee arthroplasty surgery. However, many of these selected topics continue to have a component of ongoing controversy with no definitive conclusions developed in recent literature.

**Total knee arthroplasty (TKA) is a very commonly done orthopaedic procedure, and therefore, any improvements in technique may have a notable effect on the patient cohort.** Despite the frequency of TKA, there are notable variations in techniques with many controversies existing. This review article examines updates to the literature during the past five years on numerous topics which were felt to have ongoing controversy or discrepancies between the techniques used by orthopaedic surgeons. In this article, attention is focused on venous thromboprophylaxis, tranexamic acid usage, tourniquet usage, and wound closure techniques. Venous thromboembolism is unfortunately a serious complication after TKA that is associated with notable patient morbidity, mortality, and economic cost.1 Tranexamic acid prophylaxis has been a topic of
ongoing debate with literature and guidelines providing a variety of pharmacologic recommendations.1
With the introduction of tranexamic acid, the likelihood of a transfusion after TKA has dramatically decreased.2,3 Still, there is discrepancies regarding the most appropriate dosage, frequency, and preferred route of administration for tranexamic acid.4-7 Tourniquet usage during TKA has become routine to improve exposure and to enhance cementing techniques. However, some argue tourniquet use causes no difference in cement penetration and can be associated with residual thigh pain and quadriceps weakness.8-10 Wound closure is a critical aspect of TKA because it influences outcomes, patient satisfaction, and overall costs.11 Numerous closure materials exist including traditional sutures, barbed sutures, staples, and adhesives. In addition, there has been ongoing debate regarding the optimal position of the knee during closure for optimal soft-tissue repair and postoperative range of motion (ROM).

This review was not intended to be a comprehensive review of all these specific topics, but rather to be a compilation overview of updates to the literature from the past five years. By analyzing the results of recent studies, we can implement the most up-to-date and evidence-based care for our patients when doing TKA surgery.

Methods

For this review, four topics were selected that were felt to have the most ongoing controversy among orthopaedic surgeons and in the literature. These topics are venous thromboprophylaxis, tranexamic acid usage, tourniquet usage, and wound closure techniques. For each individual topic, a literature search was conducted on several databases that included but was not limited to PubMed, the University of Saskatchewan Online Library Catalogue, the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), and Google Scholar. Searches were conducted using a variety of search terms related to each specific topic in addition to the following terms: total knee arthroplasty, total knee replacement, total knee, and arthroplasty. As the focus of this study was to examine updates to the literature, emphasis was placed on studies that were published in the past 5 years (2014 to 2018 inclusive), with exceptions made in the case to provide background information on a topic, or studies that contain the most recently available data. Preference was given to meta-analyses, randomized controlled trials, and commonly used guideline sources, although other studies of lower level of evidence were included as required. Only articles and guidelines written in English and that were available in full-text format were included. For topics with numerous studies available from the past 5 years, the outcomes of each study were compiled into a table format.

Venous Thromboprophylaxis

Venous thromboembolism (VTE) is a complication after TKA that is associated with notable patient morbidity, mortality, and economic cost. Thromboprophylaxis has been a topic of ongoing debate with literature and guidelines providing a variety of recommendations.1

Thromboprophylaxis can be divided into mechanical and pharmacologic prevention. Mechanical methods include mobilization, graduated compression stockings, and intermittent pneumatic compression devices (IPCDs).1 IPCDs can have a relative risk reduction for deep venous thrombosis (DVT) and pulmonary embolism (PE) of greater than 50%, without the risk of bleeding, or any other notable complication.12 However, compliance remains a major challenge limiting their use.12 Given the possible effectiveness combined with the low-risk profile, the American College of Chest Physicians (ACCP) recommends dual prophylaxis with an antithrombotic agent and an IPCD during the hospital stay (grade 2C).12

Pharmacologic Methods

Pharmacological methods of prophylaxis include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), vitamin K antagonists (VKAs), synthetic pentasaccharide factor Xa inhibitors (fondaparinux), newer oral anticoagulants (ie rivaroxaban, dabigatran, and apixaban), and aspirin. The most appropriate agent, along with duration of therapy, has been the focus of notable attention in TKA literature. There are many guidelines published (Table 1), although discrepancies continue to persist mainly because of the lack of evidence supporting one particular agent or regimen. The latest 2012 evidence-based guidelines from the American College of Chest Physicians (ACCP) provide suggestions based on efficacy while balancing safety that can assist with choosing a prophylactic regimen.12 Although they maintain a preference for LMWH based on its long-term safety data,12 rivaroxaban and aspirin have become more popular agents.

Unfractionated Heparin

UFH is a mixture of glycosaminoglycans that inactivates thrombin, factor Xa, along with other coagulation enzymes. It is not absorbed orally so must be given parenterally. The ACCP estimates the effect of low-dose UFH to be a reduction of 13 symptomatic VTEs per 1000 patients undergoing major orthopaedic surgery.12 Major risks
include major bleeding and heparin-induced thrombocytopenia (HIT).\(^1\)

**Low-Molecular-Weight Heparin**

LMWH is formed by depolymerization of UFH. It has greater activity against factor Xa than thrombin and has more predictable pharmacokinetic and pharmacodynamic properties than UFH.\(^1\) Longer half-life results in less frequent parenteral dosing.\(^1\) The risk of HIT is still present but reduced.\(^1\) The ACCP considers LMWH the benchmark to compare other agents against and makes the suggestion to use LMWH over other agents based mainly on its longer safety record.\(^1,12\) Although the synthetic pentasaccharide fondaparinux has greater activity against factor Xa than LMWH, it has a greater half life, and does not cause HIT, it is still less appealing for DVT prophylaxis because of its adverse events\(^1\) (i.e. major bleeding requiring reoperation 4 more per 1000 compared with LMWH).\(^1,12\)

**Vitamin K Antagonists**

VKAs (i.e., warfarin) are a group of oral anticoagulants that interfere with the cyclic interconversion of vitamin K and its 2,3 epoxide. The use of VKAs

### Table 1

| Guidelines | Recommendations | Duration of Prophylaxis |
|------------|-----------------|-------------------------|
| **ACCP (2012)**\(^1,12\) | Preference: LMWH Other acceptable options: low-dose UFH, VKA, fondaparinux, apixaban, dabigatran, rivaroxaban, aspirin, or IPCD Recommends dual prophylaxis with addition of intermittent pneumatic device (IPCD) during the hospital stay | Minimum 10-14 days but suggest extending up to 35 days |
| **NICE\(^20\)** | Choose one of: Aspirin (75 or 150 mg) LMWH + antiembolism stockings (until D/C) Rivaroxaban Consider apixaban or dabigatran if the above cannot be used | 14 days 14 days 14 days |
| **Thrombosis Canada\(^21\)** | Rivaroxaban (10 mg PO daily) Apixaban (2.5 mg PO BID) Dabigatran (220 mg PO daily) Enoxaparin (30 mg SC BID or 40 mg SC daily) Dalteparin (5000 U SC daily) Tinzaparin (4500 U or 75 U/kg SC daily) Fondaparinux (2.5 mg SC daily) Nadroparin (38 U/kg SC daily (day 1-3 postop), 57 U/kg SC daily (day 4 +) Patients not at high VTE risk: consider rivaroxaban until postoperative day 5 then ASA 81 mg daily for 9 additional days ASA alone and VKAs not included given accessibility of more effective and equally or more convenient alternatives | 14-35 days Suggest longer duration for patients at greater risk including bilateral TKA, previous VTE, and substantially impaired mobility at discharge |
| **SIGN\(^22\)** | Acceptable options (combined with mechanical prophylaxis unless contraindicated): LMWH, fondaparinux, rivaroxaban, and dabigatran Aspirin NOT recommended as sole pharmacological agent | Optimal duration unclear Extended prophylaxis should be given |
| **AAOS\(^23\)** | Unable to recommend for or against specific prophylactics Current evidence unclear about which prophylactic strategy or strategies is/are optimal or suboptimal | Patients and physicians discuss the duration of prophylaxis due to lack of reliable evidence |

AAOS = American Academy of Orthopaedic Surgeons; ACCP = American College of Chest Physicians; BID = twice daily; LMWH = low-molecular-weight heparin; PO = orally; SIGN = Scottish Intercollegiate Guidelines Network, NICE = National Institute for Health and Care Excellence; TKA = total knee arthroplasty; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = Venous thromboembolism; D/C = patient discharge; SC = subcutaneous injection
requires ongoing monitoring, and the benefit of its use is closely balanced by a possible increase of major bleeding.\textsuperscript{1,12} Although the latest ACCP guidelines recommend VKAs as an acceptable option,\textsuperscript{1} the delays in achieving therapeutic effect, as well as interactions with other medications and dietary changes, make it a less desirable option.\textsuperscript{13}

**Novel Oral Anticoagulants**

The major advantage of the new oral anticoagulants is the ability to be administered orally at regular intervals and without the need for monitoring. Rivaroxaban and apixaban are direct factor Xa inhibitors. Rivaroxaban was more effective for VTE prevention than enoxaparin after TKA in phase III clinical trials.\textsuperscript{1} However, it has an increased risk of bleeding.\textsuperscript{12} Apixaban has similar efficacy and comparable risk of major bleeding as LMWH.\textsuperscript{12} Dabigatran is a reversible, direct thrombin inhibitor and was found to be as effective as enoxaparin for VTE prophylaxis, with a similar propensity to cause bleeding.\textsuperscript{1} The latest ACCP guidelines recommend all three of these agents, although they suggest the greater long-term experience with LMWH still favors its use.\textsuperscript{1}

Ma et al in a meta-analysis that included 13,790 TKA patients found the overall incidence of DVT to be significantly less with the use of rivaroxaban (relative risk [RR] = 0.59, \( P < 0.01 \)) and apixaban (RR = 0.60, \( P < 0.01 \)) compared with enoxaparin, although there was no significant difference in the rates of PE. In addition, there was no significant difference in the rates of major bleeding.\textsuperscript{14}

Guang-Zhi et al in a meta-analysis that included nine trials and 15,829 patients with total hip arthroplasty (THA) and TKA similarly reported that compared with enoxaparin, rivaroxaban had significantly lower rates of symptomatic DVT (RR = 0.36, \( P = 0.0001 \)), but not the rate of symptomatic PE (RR = 0.79, \( P = 0.57 \)). However, they suggested that rivaroxaban was associated with a significant increased risk of major bleeding (RR = 1.37, \( P = 0.02 \)), but was not different in terms of all-cause mortality (RR = 0.63, \( P = 0.27 \)). Ultimately, they suggested more evidence is needed to verify the risk of major bleeding with rivaroxaban.\textsuperscript{15}

Kapoor et al in a network meta-analysis including 94 studies analyzed the efficacy of VTE prophylaxis, and safety in avoiding hemorrhage, in 12 different prophylactic strategies. Relative to LMWH, direct oral Xa inhibitors had markedly lower rates of DVT (odds ratio [OR] 0.45; 95\% confidence interval [95\% CI] 0.35 to 0.57). Aspirin was done similarly to LMWH, while VKA predicted 56\% more DVT events.

When including only symptomatic DVTs, direct factor Xa inhibitors led to 4-fold fewer symptomatic DVTs (OR 0.25, 0.13 to 0.47), while small study numbers and event rates limited the conclusions of all other strategies. Compared with LMWH, direct oral Xa inhibitors had increased rates of major bleeding (OR 1.21, 95\% CI 0.79 to 1.90), although not statistically significant. VKA and aspirin performed equally to LMWH in terms of efficacy and major bleeding. Overall, they suggest direct oral Xa inhibitors have the most desirable profile when considering efficacy and avoidance of major bleeding, while VKA has an unfavorable profile and aspirin an indeterminate profile.\textsuperscript{16}

**Aspirin**

The use of aspirin has increased since the latest ACCP guideline (2012) considered it an acceptable agent. It is less effective at VTE prophylaxis than other agents, but may be associated with a lower risk of bleeding.\textsuperscript{17} This change in ACCP recommendations was based on the Pulmonary Embolism Prevention Trial which involved 4088 elective hip and knee arthroplasty patients and 13,356 hip fracture patients with a 36\% reduction in symptomatic DVT rate among the hip fracture group.\textsuperscript{17} There was no observed difference in rates between aspirin and placebo in the arthroplasty group, and overall, there was a trend toward more major bleeding with aspirin.\textsuperscript{17} However, the ACCP suggested the data were sufficient to recommend aspirin as a prophylactic option compared with no prophylaxis.\textsuperscript{12,17}

Drescher et al in a systematic review and meta-analysis studied 8 trials with 1408 patients after hip fracture surgery, THA, and TKA. When comparing aspirin to all other anticoagulants (studies were included that compared aspirin against VKA, UFH, LMWH, thrombin inhibitors, pentasaccharides, and factor Xa/IIa inhibitors dosed for VTE prevention), they found there was no difference in rates of proximal DVT after knee or hip arthroplasty (9.3\% versus 9.7\%, RR: 1.00; 95\% CI: 0.49 to 2.05). The absolute number of PEs was higher in the aspirin group, although the frequency was low, and the difference was not statistically significant. The difference in rates of all bleeding events (aspirin 3.9\%, anticoagulants 7.8\%), as well as major bleeding (aspirin 2.1\% versus anticoagulants 0.6\%), was not statistically significant between aspirin and anticoagulants for the lower extremity arthroplasty group. They concluded the balance between VTE and bleeding risks suggests that aspirin may be favorable after elective TKA.\textsuperscript{18}

An et al\textsuperscript{19} have done a systematic review and meta-analysis involving 69,551 THAs and TKAs. The overall rate of VTE was low (DVT 1.2\%, PE 0.6\%) when aspirin was used as prophylaxis, with the rate of major
bleeding only 0.3%. However, they found that the quality of evidence was limited.

Hybrid strategies have also emerged with numerous regimens suggested. Anderson et al performed a multi-center, double-blind, randomized controlled trial (RCT) of 3424 patients undergoing THA or TKA either randomized to continuation of rivaroxaban or changed to aspirin 81 mg after an initial 5-day course of rivaroxaban. There was no significant difference in prevention of symptomatic VTE (0.64% ASA, 0.70% rivaroxaban; \( P < 0.001 \) for non-inferiority) or major bleeding (0.47% aspirin, 0.29% rivaroxaban; \( P = 0.42 \)).

The low price and accessibility, along with oral administration, make aspirin an enticing choice, although its use for VTE prophylaxis still remains controversial. Although the ACCP (2012) and NICE (2018) guidelines include aspirin as an acceptable option, Thrombosis Canada (2018) did not include aspirin alone as a suggested option, the SIGN (2015) guidelines continue to recommend against aspirin as a sole agent given the greater effectiveness of other agents, and the Efort 2018 Review “remains skeptical about the use of aspirin as a sole method of prophylaxis.”

**Venous Thromboprophylaxis Summary**

Choosing the appropriate method of prophylaxis for your patient requires a thorough knowledge of the available agents, specifically their efficacy and risk profiles. There are many guidelines published (Table 1), and the ACCP provides a thorough review based on efficacy and risk. The ACCP continues to suggest tinzaparin over other agents based on its long-term risk data; however, many studies have shown direct factor Xa inhibitors such as rivaroxaban to have an equivalent or greater reduction in symptomatic VTE rates, with a similar risk profile. The use of aspirin has become increasingly popular, with numerous studies suggesting a similar efficacy in VTE prevention compared with anticoagulants, along with a favorable risk profile. However, the use of aspirin for VTE prophylaxis does still remain controversial, and although its use is supported by several guidelines, others recommend against it, and additional investigation would be beneficial before making firm conclusions.

The ACCP recommends consideration be given to extend prophylaxis up to 35 days, rather than only 10 to 14 days, and the Thrombosis Canada guidelines also recommend a duration of 14 to 35 days with a longer duration for those patients at higher risk.

Based on ACCP guidelines, dual prophylaxis with the addition of IPCDs while in hospital should be done.

**Tranexamic Acid Usage**

TKA is a major surgery associated with blood loss, which could lead to a transfusion postoperatively. Allelo- genetic transfusions do have risks to the patient, which could lead to an inferior result. These risks include increased infection rate, metabolite abnormalities, hemolysis, and blood-borne illnesses. With the introduction of tranexamic acid, the likelihood of a transfusion has dramatically decreased. Still, there is some controversy regarding the dosage, frequency, and preferred route of administration for tranexamic acid. Certainly, when adding a new medication such as tranexamic acid, one has to be certain that there will not be resultant adverse events such as deep vein thrombosis or pulmonary embolism. By focusing on randomized controlled trials over the past 5 years, we attempted to answer these aforementioned questions.

There are three main routes that tranexamic acid is administered. They are as follows: intravenously at weight adjusted doses ranging from (10–20) mg/kg 2 hours preoperatively; orally with 2 g dispensed 2 hours preoperatively; and intratumorally by injecting 1 to 3 g mixed with 20–100 cc of normal saline into the joint once the artthroscopy has been closed.

After adminstering the first oral or intravenous tranexamic acid dose, multiple subsequent doses can be given (oral dose: 1 g; intravenous dose: 10 mg/kg). This can include one to four additional doses given at time intervals varying from 3 hours, 6 hours, 9 hours, 12 hours, and 15 hours after surgery. Oral administration can follow an initial intravenous dose; however, the opposite order of administration does not usually occur.

When we look at all the evidence accumulated over the past 5 years, there are no clear answers as to which route, dosage, combination of drugs, and frequency are the best. However, conclusions can be made with the evidence at hand. Comparing oral administration to intravenous administration, there appears to be no difference in outcomes. This seems to be similar comparing intravenous administration to intra-articular administration, as well as oral administration matching to intra-articular administration.

When evaluating the ideal frequency, there are many studies demonstrating benefit with multiple subsequent dosages compared with a single dose. The total number of doses and the frequency of the dosages still remain unclear with some studies showing clear benefit administering tranexamic acid at 3-hour intervals for four subsequent doses, while other studies show no benefit of adding even a third...
additional dose. The latter spaced the doses 6 hours apart (3 hours, 9 hours, and 15 hours postoperatively).

Combining routes, such as administering an intravenous dose followed by oral dosing or intravenous followed by intra-articular dosing, does seem to offer better results. Tranexamic acid does not appear to lead to higher morbidity as seen in multiple studies. However, patients excluded from these studies included previous deep vein thrombosis or pulmonary embolism in the past 6 months, serious cardiac or cerebrovascular issues, preoperative hepatic or renal dysfunction, bilateral procedures, and coagulation disorders; therefore, it is difficult to know whether tranexamic acid is safe in all patients.

In summary
Tranexamic acid is a crucial addition in total knee replacements. It has been proven to be safe and effective in reducing blood loss, without notable risk to the patient. Using oral tranexamic acid is a cheap alternative to the more expensive intra-articular and intravenous administrations. Consideration should be given to using multiple doses (at least two) in the acute postoperative period along with combining different routes of administration.

Tourniquet Usage
Tourniquet usage during TKA has become routine to improve exposure and to enhance cementing techniques. Multiple studies have been cited to demonstrate poor cement penetration if the cement is contaminated with circulating blood or tissue products. Alternatively, numerous studies have demonstrated no difference in cement penetration during cementation whether a tourniquet was used or not. It has also been shown that using a tourniquet for a prolonged period can cause quadriceps weakness, residual pain in the thigh, excessive inflammation, and muscle damage.

The tourniquet can be inflated during multiple stages of the TKA including at the time of skin incision or just prior to cementing. Deflation can occur once the cement hardens or once the dressing and compressive bandage has been applied. Table 2 shows recent evidence regarding tourniquet use in respect to differences in blood loss, surgical time, postoperative pain, and ROM. It has been shown that intraoperative blood loss and operating time are markedly reduced when using a tourniquet during a TKA. However, total blood loss was similar whether the tourniquet was inflated at the beginning of the case or just before cementing. This can be explained by an increase in postoperative blood loss in the tourniquet group. Greater care is taken to obtain hemostasis intraoperatively in the no tourniquet (NT) or limited tourniquet (LT) groups compared with the bloodless field in the tourniquet group, which subsequently leads to less postoperative blood loss. This can also explain why the total operating time is increased in the NT and LT groups. Multiple studies demonstrated stronger quadriceps strength and better ROM in the NT and LT groups. NT or LT use also leads to less swelling and postoperative pain. This can be explained by the decrease in inflammation seen in the musculature with LT or NT usage.

In summary
The results of tourniquet usage are still very controversial. There is, however, a tendency to less pain, better ROM, and increased quadriceps strength with no tourniquet or limited tourniquet usage at a cost of longer operating times. These aforementioned benefits are mainly evident in the first several weeks after TKA. In seeking the ultimate pain strategy after TKA to attempt to improve outcomes, no tourniquet or limited tourniquet usage could form part of the holistic approach. Although it may result in slightly longer surgical times, it is a simple intervention which could lead to better patient outcomes with very minimal risk, including no difference in total blood loss.

Wound Closure
Wound closure is a critical aspect of TKA as it influences outcomes, patient satisfaction, and overall costs. Suboptimal closure can lead to higher rates of wound complications including superficial and deep infections, abscess formation, dehiscence, and poor cosmesis. The ideal wound closure should optimize healing and reduce infection while producing a satisfactory scar. Closure techniques that aim to decrease surgical time, along with complications, will ultimately reduce total costs as well. Numerous closure materials exist including traditional sutures, barbed sutures, staples, and adhesives.

Sutures are the traditional method for deep and superficial closure and continue to be one of the most commonly used methods. Sutures reliably continue to be one of the most common methods. Sutures reliably provide adequate closure at the cost of increased surgical time. More recently barbed sutures have gained popularity for both superficial and deep wound closure. These sutures have unidirectional or bidirectional barbs, eliminating the need for knots. This can lead to faster application, and it has been suggested that they are more resistant to failure due to multiple points of adherence. Stainless steel staples along with traditional sutures are the most common methods of superficial closure. Staples can be efficiently inserted and removed, although removal can cause some patient discomfort.
Adhesives can be used as a substitute to or in addition to cutaneous sutures. When used as a substitute, the subcutaneous tissue is often reinforced with greater amounts of suture which may negate any time saved by using the adhesive.11 Adhesives are less commonly used than sutures or staples and will not be focused on in this review.

The optimal technique for wound closure is still debatable with different materials being available for both superficial and deep closure, each with advantages and disadvantages. There have been numerous studies comparing the options while focusing on variables such as wound complications, closure time, overall costs, and cosmesis (Table 3).11,32-35

### Deep Closure

For deep closure, the traditional method has been interrupted sutures, although there has been an increasing use of barbed sutures. Krebs et al11 suggested deep closure was fastest with barbed sutures with no difference in complications or cosmesis compared with traditional sutures. The resultant decrease in resources and faster surgical times also have potential for cost savings. Ultimately, the authors suggested more studies were needed to make firm recommendations. A meta-analysis by Zhang et al34 also found no difference in complications, along with improved time and cost savings, and suggested barbed sutures were the optimal method for closure of the arthrotomy, subcutaneous, and subcuticular layers.

### Superficial Closure

For superficial closure, sutures were again the traditional method and continue to be one of the most common methods along with staples. In the aforementioned review by Krebs et al,11 they suggested staples decrease surgical time over sutures, while sutures may have improved tissue blood flow and healing. They did not note any notable differences between the two options in terms of wound complications or cosmesis. Kim et al also suggested that staples

---

**Table 2**

| Study Comparison | Type of Study | Patients | Total Blood Loss | Total Surgical Time | Postoperative Pain | Range of Motion | Length of Stay |
|------------------|---------------|----------|------------------|---------------------|--------------------|----------------|----------------|
| Zhou et al26—NT versus T | Prospective double-blinded RCT | 150 | No difference | Better in the T group ($P < 0.001$) | Better in the NT group ($P = 0.005$) | Better in the NT group ($P < 0.001$) | Not reported |
| Liu et al30—NT versus T | Prospective RCT | 52 | Not reported | Better in the T group ($P < 0.05$) | Better in the NT group ($P < 0.05$) | No difference | Not reported |
| Wang et al3—LT versus T | Observer blinded RCT | 50 | Better in the T group ($P: 0.0411$) | Better in the T group ($P: 0.0449$) | Better in the LT group | Better in the LT group | Not reported |
| Harsten et al31—T versus NT | RCT | 64 | Not reported | Not reported | No difference | No difference | No difference |
| Fan et al27—T versus LT | RCT | 60 | No difference | No difference | Better in the LT group ($P < 0.001$) | Better in the LT group ($P < 0.001$) | Not reported |
| Ejaz et al29—T versus NT | RCT | 70 | Not reported | No difference | Better in the NT group ($P: 0.02$) | Better in the NT group | Not reported |
| Tarwala et al28—LT versus T | RCT | 71 | No difference | No difference | No difference | No difference | Not reported |

---

**Figure 1**

Photograph of Covidien V-Loc 180 suture demonstrating an example of unidirectional barbed suture.
may have a subtle advantage over sutures. Although statistically insignificant, the rates of superficial and deep infection, as well as wound dehiscence, favored staples. In addition, staples had improved surgical times with a resultant decrease in overall resource utilization. However, both of these articles suggested more studies are necessary.11,32 More recently barbed sutures have also been introduced for superficial closure.13

### Table 3

Comparison of Recent Studies Evaluating Traditional Sutures (TS), Barbed Sutures (BS), and Staples (S) for Wound Closure in TKA

| Study Comparison | Wound Complications | Closure Time | Cost | Cosmesis | Recommendation |
|------------------|---------------------|-------------|------|----------|----------------|
| Krebs et al11 (evidence-based review 2018) (TS) versus (BS) versus (S) | No notable difference (4 studies) Superior blood flow with subcuticular (TS) versus (S) (2 studies) | Deep: faster with (BS) versus (TS) (5 studies) Superficial: faster (S) versus (TS) (4 studies) (S) versus (BS) more study needed | Potential savings with (BS) due to faster surgical time and fewer resources used | No difference (TS) versus (S) (2 studies) | No optimal closure technique developed More studies needed Deep closure: (BS) fastest with similar complications (TS) Superficial closure: (S) fastest, (TS) may have improved blood flow/healing, more studies necessary to evaluate (BS) for superficial layers |
| Kim et al32 (meta-analysis and systematic review)—8 studies, 828 TKAs (TS) versus (S) for superficial closure | Favored (S) for both deep and superficial infection although not statistically significant | Faster with (S) | Overall reduction in resource utilization with (S) Eggers et al33 total intraoperative costs: $1023.50 USD (TS) and $636.70 USD (S) | Not reported | (S) may have subtle clinical advantages over (TS) for superficial closure More study needed |
| Zhang et al34 (systematic review and meta-analysis) 9 articles, 1729 patients (BS) versus (TS) | No difference $P = 0.38$ | (BS) 3.56 minutes faster than (TS) ($P < 0.01$) | (BS) = average $290.72 USD savings over (TS) ($P < 0.01$) | Not reported | (BS) leads to shorter OR times + decreased costs over (TS) Suggest (BS) is optimal method for closure of arthrotony, subcutaneous, and subcuticular layers |
| Campbell et al35—retrospective review—416 pts 247 (S), 129 (BS) (BS) versus (TS) superficial closure | Superficial infection: 3.2% (S), 11.8% (BS); $P = 0.001$ Deep infection: 0.8% (S), 4.7% (BS); $P = 0.018$ Dehiscence: 1.2% (S), 4.1% (BS) $P = 0.098$ | Not reported | Not reported | Not reported | (BS) should be avoided for superficial closure |

TKA = total knee arthroplasty
Closure, although evidence is more limited. In the meta-analysis by Zhang, they suggested that decreased surgical time, overall cost, with no difference in complications makes barbed sutures the optimal method for superficial closure over traditional suture. This is in stark contrast to Solovyova et al. who suggested in their mini-review that when used for subcuticular or skin closure, there are several studies that show increased wound complications with barbed suture. Campbell et al also demonstrated increased rates of both superficial and deep infection after using barbed suture for superficial closure. Several studies have demonstrated that barbed suture is more efficient than traditional suture and has no difference in complication rates when used for arthroscopy closure. However, as several studies show increased rates of wound complications, barbed sutures may not be the optimal choice for superficial closure at this point until further evidence emerges.

**Knee Position for Closure**

There has been ongoing debate regarding the optimal position of the knee during closure for optimal soft-tissue repair and postoperative ROM. King et al initially described closing the knee in deep flexion (90 to 120°) to cause less stretching of soft tissues potentially leading to less patient discomfort, along with preventing extensor mechanism shortening with resultant increased tension with deep knee flexion. Evidence in the past has been limited, and therefore, the method of closing the wound has been based on surgeon preference. More recent literature (Table 4) is still indeterminate with minimal differences noted in long-term flexion ROM, function, or complications. However, Faour et al in a review of seven studies including 516 patients noted improved early ROM, faster functional recovery, comparable satisfaction, and no higher risk with wound closure in flexion; therefore, closure in flexion may have potential advantage compared with extension.

### Table 4

| Study Comparison | Post-Operative ROM | Function | Complications | Recommendation |
|------------------|--------------------|----------|---------------|----------------|
| Faour et al (2018) Literature Review | Improved early ROM with (F) (4 positive, 3 neutral studies) | Improved early postop pain scores (2 positive, 1 neutral study), faster functional recovery (2 studies) with (F) | No difference in wound-related complications (seven neutral studies) | May have improved early ROM, faster functional recovery, comparable satisfaction, and no higher risk with wound closure in flexion; therefore, closure in flexion may have potential advantage compared with extension |
| Cerciello et al (2016) systematic review | Variable at time of closure (60 to 110° [F]) | No differences at final f/u: KSS (45.8 [F], 48.2 [E], AKSS (20.2 [F], 20.8 [E]), VAS (1.2 [F], 1.1 [E]) | No differences | No clear advantage to capsule closure in flexion or extension |
| Motififard et al (2016) Double-blind prospective RCT, 85 patients | No differences After 1 week, 2 weeks, 4 weeks, 6 months, or 12 months (P < 0.05) | No differences KSS after 12 months: Knee score 71.8 ± 10.9 (F), 74.3 ± 11.5 (E), Function Score 68.3 ± 12.1 (F), 68.4 ± 14.7 (E) | Not reported | Wound closure position does not affect postop flexion ROM or KSS |

TKA = total knee arthroplasty
In flexion may have a potential advantage compared with closure in extension. However, more evidence is required to make definitive conclusions, and the choice can be made based on surgeon preference.

In summary:
For deep closure (arthrotomy), current evidence suggests both traditional and barbed sutures have similar rates of complications and overall cosmesis. However, improved surgical times with barbed sutures, along with a resultant decrease in overall costs, may provide a slight advantage over traditional suture. For superficial closure, sutures and staples are both acceptable options with similar rates of wound complications and cosmetic outcomes. However, improved surgical times and resultant costs may favor staples, although with increased patient discomfort at removal. The evidence for superficial barbed sutures is mixed, likely making them a less desirable option than staples or sutures. Based on the current evidence, there is no notable difference in long-term outcomes between wound closure with the knee in flexion or extension, although it has been suggested that there may be some benefit to the patient in the early recovery period with closing the knee in flexion. However, as more evidence is required, the decision can continue to be made based on surgeon preference.

Summary
There are numerous controversial topics in total knee arthroplasty and four of these areas were addressed in this particular review article. Despite the evolution of literature specific to these topics, there continues to be an amount of uncertainty regarding the most beneficial and appropriate treatment choices. Based on this review, tranexamic acid is a safe and effective treatment to reduce blood loss. Consideration should be given to use multiple doses of tranexamic acid and to combine different modes of administration. Limited tourniquet use or no tourniquet use do show a tendency to better patient satisfaction at a cost of longer operating times. Barbed sutures might be beneficial in deep arthroscopy closure, but staples or sutures are still recommended for skin closure. There may be some benefit to close the knee in flexion. The evidence is clear that we should use postoperative anti-coagulation. Thromboprophylaxis should be individualized to the patient, and anti-coagulation administered with a thorough knowledge of their efficacy and risk profiles. Consideration should be given to extend anti-coagulation to 35 days postoperatively. The conclusions that we arrived at were based on studies done in the past five years and are certainly not a comprehensive overview of each of the topics. Orthopaedic surgeons should use these recommendations cautiously and only as an adjunct to their existing knowledge about the topic. There has been an abundance of literature published in the past five years attempting to address these problems with total knee arthroplasty, and future studies will only continue to improve the functional outcomes and satisfaction of patients.

References
1. Eleva DV, Megaloikonomos PD, Dimopoulos L, Mitsiopapa E, Koulouvaris P, Mavrogenis AF: Thromboembolism prophylaxis in orthopaedics: An update. EFORT Open Rev 2018;3:136-48.
2. Fillingham YA, Kayupov E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ: The James A. Rand Young Investigator’s Award: A randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: The same efficacy at lower cost? J Arthroplasty 2016;31: 26-30.
3. Stowers MD, Aiona J, Vane A, Poutawera V, Hill AG, Munro JT: Tranexamic acid in knee surgery study—a multicentered, randomized, controlled trial. J Arthroplasty 2017;32:3379-84.
4. Wang D, Wang HY, Luo ZY, et al: Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: A randomized controlled trial. Bone Joint J 2018;100-b: 1025-32.
5. Lei Y, Xie J, Xu B, Xie X, Huang Q, Pei F: The efficacy and safety of multiple-dose intravenous tranexamic acid on blood loss following total knee arthroplasty: A randomized controlled trial. Int Orthop 2017;41:2053-9.
6. Lee S, Chong S, Balasubramanian D, Na Y, Kim T: What is the ideal route of administration of tranexamic acid in TKA? A randomized controlled trial. Clin Orthop Relat Res 2017;475:1987-96.
7. Cankaya D, Dasar U, Satilmis AB, Basaran SH, Akkaya M, Bozkurt M: The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. J Orthop Surg (Hong Kong) 2017;25: 230949016684725.
8. Ozkunt O, Sarayılmaz K, Gemalmaz HC, Dikici F: The effect of tourniquet usage on cement penetration in total knee arthroplasty. Medicine (Baltimore) 2018;97:e9668.
9. Wang K, Ni S, Li Z, et al: The effects of tourniquet use in total knee arthroplasty: A randomized, controlled trial. Knee Surg Sports Traumatol Arthrosc 2017;25: 2849-57.
10. Dennis D, Kittelson A, Yang C, Miner T, Kim R, Stevens-Lapsley J: Does tourniquet use in TKA Affect recovery of lower extremity strength and function? A randomized trial. Clin Orthop Relat Res 2016;474:69-77.
11. Krebs VE, Elmallah RK, Khlopas A, et al: Wound closure techniques for total knee arthroplasty: An evidence-based review of the literature. J Arthroplasty 2018;33: 633-8.
12. Falck-Ytter Y, Francis CW, Johanson NA, et al: Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e27S-e32S.
13. Anderson DR, Dunbar M, Murnaghan J, et al: Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018;378:699-707.
14. Ma G, Zhang R, Wu X, Wang D, Ying K: Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. *Thromb Res* 2015;135:816-22.

15. Guang-Zhi N, Shun-Li K, Ling-Xiao C, Lei S, Shi-Qing F, Yue Z: Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: A meta-analysis with trial sequential analysis of randomized controlled trials. *Sci Rep* 2016;6:23726.

16. Kapoor A, Ellis A, Shaffer N, et al: Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: A network meta-analysis. *J Thromb Haemost* 2017;15:284-94.

17. Lieberman JR, Heckmann N: Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: From guidelines to practice. *J Am Acad Orthop Surgeons* 2017;25:789-98.

18. Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ: Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: A systematic review and meta-analysis. *J Hosp Med* 2014;9:579-85.

19. An VVG, Phan K, Levy YD, Bruce WJM: Aspirin as thromboprophylaxis in hip and knee arthroplasty: A systematic review and meta-analysis. *J Arthroplasty* 2016;31:2608-16.

20. National Institute for Health and Clinical Excellence: Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. https://www.nice.org.uk/guidance/ng89. Accessed December 27, 2018.

21. Thrombosis Canada: *Thromboprophylaxis: Orthopedic Surgery*, http://thrombosiscanada.ca/wp-content/uploads/2018/03/Thromboprophylaxis-Orthopedic-2018Feb21-Final.pdf. Accessed December 27, 2018.

22. Scottish Intercollegiate Guidelines Network (SIGN): Prevention and management of venous thromboembolism. https://www.sign.ac.uk/sign-122-prevention-and-management-of-venous-thromboembolism.html Accessed December 28, 2018.

23. American Academy of Orthopaedic Surgeons: Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. Evidence-based guidelines and evidence report. http://www.aaos.org/research/guidelines/vte/vte_full_guideline.pdf Accessed December 28, 2018.

24. Subramanyam KN, Khanchandani P, Tuljaprasad PV, Jaipuria J, Mundargi AV: Efficacy and safety of intra-articular versus intravenous tranexamic acid in reducing perioperative blood loss in total knee arthroplasty: A prospective randomized double-blind equivalence trial. *Bone Joint J* 2018;100B:152-60.

25. George J, Echempati KK, Subramanyam KN, Gurava Reddy AV: The comparative efficacy and safety of topical and intravenous tranexamic acid for reducing perioperative blood loss in total knee arthroplasty— a randomized controlled non-inferiority trial. *Knee* 2018;25:183-91.

26. Zhou K, Ling T, Wang H, et al: Influence of tourniquet use in primary total knee arthroplasty with drainage: A prospective randomised controlled trial (clinical report). *J Orthop Surg Res* 2017;12:172.

27. Fan Y, Jin J, Sun Z, et al: The limited use of a tourniquet during total knee arthroplasty with drainage: A prospective randomised controlled trial (clinical report). *J Orthop Surg Res* 2017;12:172.

28. Tarwala R, Dorr LD, Gilbert PK, Wan Z, Long WT: Tourniquet use during cementation only during total knee arthroplasty: A randomized trial (report). *Clin Orthop Relat Res* 2014;472:169-174.

29. Ejaz A, Laursen AC, Kappel A, et al: Faster recovery without the use of a tourniquet in total knee arthroplasty: A randomized study of 70 patients. *Acta Orthopaedica* 2014;85:422-6.

30. Liu PL, Li Dq, Zhang Yk, et al: Effects of unilateral tourniquet used in patients undergoing simultaneous bilateral total knee arthroplasty (report). *Orthop Surg* 2017;9:180-5.

31. Harsten A, Bandholm T, Kehlet H, Toksvig-Larsen S: Tourniquet versus no tourniquet on knee-extension strength early after fast-track total knee arthroplasty: a randomized controlled trial. *Knee* 2015;22:126-30.

32. Kim KY, Anoushiravani AA, Long WJ, Vgkorichik JM, Fernandez-Madrid I, Schwarzkopf R: A meta-analysis and systematic review evaluating skin closure after total knee arthroplasty—what is the best method? *J Arthroplasty* 2017;32:2920-7.

33. Eggers MD, Fang L, Lionberger DR: A Comparison of wound closure techniques for total knee arthroplasty. *J Arthroplasty* 2011;26:1251-8.e1254.

34. Zhang W, Xue D, Yin H, et al: Barbed versus traditional sutures for wound closure in knee arthroplasty: A systematic review and meta-analysis. *Sci Rep* 2016;6:19764.

35. Campbell AL, Patrick DA, Liaubaud B, Geller JA: Superficial wound closure complications with barbed sutures following knee arthroplasty. *J Arthroplasty* 2014;29:966-9.

36. Solovyova O: The use of barbed suture for wound closure in hip and knee arthroplasty. *Biomed J Sci Tech Res* 2017;1:1391-1393.

37. King TV, Kish G, Eberhart RE, Holzaepfel JL: The “genuflex” skin closure for total knee arthroplasty. *Orthopedics* 1992;15:1057-8.

38. Gerciello S, Morris B, Lustig S, et al: The role of wound closure in total knee arthroplasty: A systematic review on knee position. *Knee Surg Sports Traumatol Arthrosc* 2016;24:3306-12.

39. Faour M, Sodhi N, Khlopas A, et al: Knee position during surgical wound closure in total knee arthroplasty: A review. *J Knee Surg* 2018;31:6-12.

40. Motifafard M, Heidari M, Nemati A: No difference between wound closure in extension or flexion for range of motion following total knee arthroplasty: A randomized clinical trial. *Knee Surg Sports Traumatol Arthrosc* 2016;24:74-8.